You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Cougar Biotechnology, Inc. is a Los Angeles-based company with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase III clinical trial in prostate cancer and a Phase I/II trial in breast cancer; CB3304, which is currently in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types. On July 10, 2009, Cougar was acquired by Johnson & Johnson.
In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology.
| Ticker: | CGRB |
| ISIN: | US2220831075 |
| Address: |
10990 Wilshire Blvd Suite 1200 |
| Los Angeles, CA, 90024, USA | |
| Website: | Cougar Biotechnology, Inc. |
| Phone #: | 310-9438040 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.